| There Are Now 5 FDA-Approved H1N1
Swine Flu Vaccines In The United States
Many have read conflicting reports on which H1N1 vaccines are
approved for use in the United States. Here is a summary of the
5 FDA approved H1N1 vaccines, including their ingredients and
toxicity.
Analysis of Toxicity,
Dosage Recommendations and Usage
2009
H1N1 Monovalent Vaccine (CSL Limited)
Toxicity:
No Squalene Present
Beta-Propiolactone:
Carcinogen
Neomycin
Sulfate: Immunotoxin
Polymyxin
B: Neurotoxin
Potassium
Chloride: Neurotoxin
Sodium
Taurodeoxycholate: Carcinogen/Immunotoxin
Thimerosal:
Neurotoxin
Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population have
not been established.
Dosage Recommendations May Lead To Toxicity:
i) Double dosing for children 6 months through 35 months
with two vaccine doses of 0.25ml/dose 4 weeks apart may lead
to deadly ethylmercury blood levels causing neurotoxicity.
ii) Double dosing for children 3-9 years of age with two vaccine
doses of 0.5ml/dose 4 weeks apart may lead to deadly ethylmercury
blood levels causing neurotoxicity.
Pregnancy
Potential harm to fetus not studied or examined.
Nursing Mothers
Potential excretion of toxic ingredients in mother's milk
not studied or examined.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or for
impairment of fertility.
Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion
of any of this vaccine's ingredients have not been studied. |
|
2009
H1N1 Monovalent Vaccine (ID Biomedical Corp of Quebec)
Toxicity:
No Squalene Present
Formaldehyde : Carcinogen
Sodium
Deoxycholate: Immunotoxin
Thimerosal:
Neurotoxin
Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population
have not been established.
Dosage Recommendations May Lead To Toxicity:
Clinical studies are still ongoing to determine the optimal
dosage, number of doses, and schedule for this vaccine.
Pregnancy
Potential harm to fetus not studied or examined.
Nursing Mothers
Potential excretion of toxic ingredients in mother's
milk not studied or examined.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or
for impairment of fertility.
Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion
of any of this vaccine's ingredients have not been studied.
|
|
2009
H1N1 Monovalent Vaccine (Novartis)
Toxicity:
No Squalene Present
Beta-Propiolactone:
Carcinogen
Polymyxin: Neurotoxin
Neomycin: Immunotoxin
Thimerosal:
Neurotoxin
Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population
have not been established.
Dosage Recommendations May Lead To Toxicity:
Double dosing for children 4 to 9 years with two vaccine
doses of 0.5ml/dose 4 weeks apart may lead to deadly ethylmercury
blood levels causing neurotoxicity.
Pregnancy
Potential harm to fetus not studied or examined.
Nursing Mothers
Potential excretion of toxic ingredients in mother's
milk not studied or examined.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or
for impairment of fertility.
Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion
of any of this vaccine's ingredients have not been studied.
|
|
2009
H1N1 Monovalent Vaccine (Sanofi Pasteur, Inc.)
Toxicity:
No Squalene Present
Formaldehyde
: Carcinogen
Polyethylene
Glycol:
Systemic Toxin
Thimerosal:
Neurotoxin
Triton X-100: Systemic
Toxin
Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population
have not been established.
Ineffective evaluation protocols in children above 6
months of age. Use may lead to toxicity.
Ineffective adverse event evaluation for this vaccine in
all teens/children under 18 years of age. Use may
lead to toxicity.
Dosage Recommendations May Lead To Toxicity:
i) Double dosing for children 6 months through 35 months
with two vaccine doses of 0.25ml/dose 4 weeks apart may
lead to deadly ethylmercury blood levels causing neurotoxicity.
ii) Double dosing for children 3-9 years of age with two
vaccine doses of 0.5ml/dose 4 weeks apart may lead to deadly
ethylmercury blood levels causing neurotoxicity.
Pregnancy
Potential harm to fetus not studied or examined.
Nursing Mothers
Potential excretion of toxic ingredients in mother's
milk not studied or examined.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or
for impairment of fertility.
Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion
of any of this vaccine's ingredients have not been studied.
|
|
2009
H1N1 Monovalent Vaccine (MedImmune LLC)
Toxicity:
Live Intranasal Virus;
No Squalene Present
Monosodium
Glutamate: Neurotoxin
Gentamicin
Sulfate: Nephrotoxic
Monobasic Potassium Phosphate:
Immunotoxin
Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population
have not been established.
Ineffective evaluation protocols in children above 2
years of age. Use may lead to toxicity.
Ineffective adverse event evaluation for this vaccine in
all teens/children under 18 years of age. Use may lead to
toxicity.
Dosage Recommendations May Lead To Toxicity:
Double dosing for children 2 to 9 years with two vaccine
doses of 0.2ml/dose 4 weeks apart may lead to deadly ethylmercury
blood levels causing neurotoxicity.
Pregnancy
Potential harm to fetus not studied or examined.
Nursing Mothers
Potential excretion of toxic ingredients in mother's
milk not studied or examined.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or
for impairment of fertility.
Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion
of any of this vaccine's ingredients have not been studied.
A biodistribution study of intranasally administered radiolabeled
placebo was conducted in 7 healthy adult volunteers. The
mean percentage of the delivered doses detected were as
follows: nasal cavity 89.7%, stomach 2.6%, brain 2.4%, and
lung 0.4%. The clinical significance of these findings
is unknown.
|
Potential Adverse
Reactions of all H1N1 Vaccines
- Pain
- Redness
- Swelling
- Fatigue
- Headaches
- Arthralgia (joint inflammation)
- Myalgia (muscle inflammation)
- Shivering
- Sweating
- Swollen lymph nodes
- Fever
- Vomiting
- Tingling or numbness of the hands or feet
- Shortness of breath
- Vasculitis (inflammation of the blood vessels)
|
Severe Potential
Reactions of all H1N1 Vaccines
- Blood and lymphatic system disorders (lymphadenopathy)
- Psychiatric disorders (insomnia)
- Nervous system disorders (dizziness, paraesthesia, inflammation
of the central nervous system, inflammation of nerves,
autoimmune disorders affecting myelin sheaths of nerves
such as Guillain-Barré Syndrome)
- Ear and labyrinth disorders (vertigo)
- Respiratory, thoracic and mediastinal disorders (dyspnoea)
- Gastrointestinal disorders (nausea, diarrhea, abdominal
pain, vomiting, dyspepsia, stomach discomfort)
- Skin and subcutaneous tissue disorders (pruritus, rash)
- Musculoskeletal and connective tissue disorders (back
pain, musculoskeletal stiffness, neck pain, muscle spasms,
pain in extremity)
- General disorders and administration site conditions
(bruising, asthenia, chest pain, malaise)
|
Dave Mihalovic is a Naturopathic Doctor who specializes in
vaccine research, cancer prevention and a natural approach to
treatment.
*
Reports
of Adverse Reactions To The H1N1 Vaccine Are Pouring In
*
Pregnant
Women Refusing H1N1 Vaccine Over Safety Fears
* Surge
in Anaphylactic Shock In B.C. From H1N1 Vaccine
*
Reactions
Being Reported From Pandemrix H1N1 Swine Flu Vaccine
*
A full list of h1n1 vaccine ingredients, alerts and warnings.
Reference Sources FDA
November 19, 2009
|
